MRNA vs. JNJ
Compare and contrast key facts about Moderna, Inc. (MRNA) and Johnson & Johnson (JNJ).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: MRNA or JNJ.
Key characteristics
| MRNA | JNJ | |
|---|---|---|
| YTD Return | 33.63% | -0.59% |
| 1Y Return | 6.04% | 0.58% |
| 3Y Return (Ann) | -5.91% | -0.51% |
| 5Y Return (Ann) | 41.96% | 5.04% |
| Sharpe Ratio | 0.11 | 0.02 |
| Daily Std Dev | 51.73% | 15.73% |
| Max Drawdown | -85.65% | -50.67% |
| Current Drawdown | -72.57% | -11.99% |
Fundamentals
| MRNA | JNJ | |
|---|---|---|
| Market Cap | $44.96B | $360.79B |
| EPS | -$15.60 | $6.73 |
| PE Ratio | 24.73 | 22.27 |
| PEG Ratio | 0.00 | 0.89 |
| Revenue (TTM) | $5.15B | $85.65B |
| Gross Profit (TTM) | $10.55B | $63.95B |
| EBITDA (TTM) | -$4.56B | $30.61B |
Correlation
The correlation between MRNA and JNJ is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
MRNA vs. JNJ - Performance Comparison
In the year-to-date period, MRNA achieves a 33.63% return, which is significantly higher than JNJ's -0.59% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
MRNA vs. JNJ - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
MRNA vs. JNJ - Dividend Comparison
MRNA has not paid dividends to shareholders, while JNJ's dividend yield for the trailing twelve months is around 3.08%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRNA Moderna, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
JNJ Johnson & Johnson | 3.08% | 3.00% | 2.52% | 2.45% | 2.53% | 2.57% | 2.74% | 2.38% | 2.73% | 2.87% | 2.64% | 2.83% |
Drawdowns
MRNA vs. JNJ - Drawdown Comparison
The maximum MRNA drawdown since its inception was -85.65%, which is greater than JNJ's maximum drawdown of -50.67%. Use the drawdown chart below to compare losses from any high point for MRNA and JNJ. For additional features, visit the drawdowns tool.
Volatility
MRNA vs. JNJ - Volatility Comparison
Moderna, Inc. (MRNA) has a higher volatility of 15.84% compared to Johnson & Johnson (JNJ) at 5.60%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than JNJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
MRNA vs. JNJ - Financials Comparison
This section allows you to compare key financial metrics between Moderna, Inc. and Johnson & Johnson. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities